tolterodine (detrol) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Tolterodine is competitive muscarinic receptors M3 and M2 antagonist. It was sold under trade names detrol for the treatment of overactive bladder with symptoms of urge urinary incontinence. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. After oral administration, tolterodine is metabolized in the liver, resulting in the formation of the 5-hydroxymethyl derivative, a major pharmacologically active metabolite. The 5-hydroxymethyl metabolite, which exhibits an antimuscarinic activity similar to that of tolterodine, contributes significantly to the therapeutic effect. Both tolterodine and the 5-hydroxymethyl metabolite exhibit a high specificity for muscarinic receptors, since both show negligible activity and affinity for other neurotransmitter receptors and other potential cellular targets, such as calcium channels. Tolterodine has a pronounced effect on bladder function. The main effects of tolterodine at 1 and 5 hours were an increase in residual urine, reflecting an incomplete emptying of the bladder, and a decrease in detrusor pressure. These findings are consistent with an antimuscarinic action on the lower urinary tract.   NCATS

Chemistry

  • SMILES: CC(C)N(CC[C@H](c1ccccc1)c2cc(C)ccc2O)C(C)C
  • InChIKey: OOGJQPCLVADCPB-HXUWFJFHSA-N
  • Mol. Mass: 325.5
  • ALogP: 5.34
  • ChEMBL Molecules:
    tolterodine  
    tolterodine tartrate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.2227 - $11.7471
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

blerone xl | detrol | detrusitol | detrusitol xl | efflosomyl xl | inconex xl | kabi-2234 | mariosea xl | neditol xl | pnu-200583e | preblacon xl | (+)-(r)-2-(alpha-(2-(diisopropylamino)ethyl)benzyl)-p-cresol | (r)-tolterodine | santizor xl | tolterodina | tolterodine | (+)-tolterodine | tolterodine tartrate | tolterodinum

Organizations (88)

Research & Development (67)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (25)

Approved Indications (1)


 

Urinary Bladder, Overactive

Experimental Indications - Clinical Trial Phases 1-4 (25)


 

Chronic Pain (Phase 4)

Cognition (Phase 4)

Dental Caries (Phase 1)

Genotype (Phase 1)

Health (Phase 2)

Healthy Volunteers (Phase 4)

Low Back Pain (Phase 3)

Lower Urinary Tract Symptoms (Phase 2/Phase 3)

Memory (Phase 4)

Neuralgia (Phase 1/Phase 2)

Pain (Phase 3)

Pelvic Organ Prolapse (Phase 3)

Pharmacokinetics (Phase 4)

Prostatic Hyperplasia (Phase 4)

Prostatic Neoplasms (Phase 4)

Sjogren's Syndrome (Phase 4)

Sleep Apnea, Obstructive (Phase 4)

Ureteral Diseases (Phase 2)

Ureteral Obstruction (Phase 4)

Urinary Bladder Neck Obstruction (Phase 4)

Urinary Bladder, Overactive ()

Urinary Incontinence (Phase 4)

Urinary Incontinence, Stress (Phase 4)

Urinary Incontinence, Urge (Phase 4)

Urination Disorders (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 84
  • # of Trial Organizations: 67

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue